非小細胞肺がんの世界市場-2023年～2030年

概要

世界の非小細胞肺がん市場は、2022年に254億米ドルに達し、2023～2030年の予測期間中にCAGR 8.4％で成長し、2030年には474億米ドルに達すると予測されます。非小細胞肺がん市場は、罹患率の増加、研究開発の進展、個別化医療、パイプラインの開発、政府の取り組みなどの要因によって牽引されています。

非小細胞肺がんの治療戦略は、がんの進行度を反映する病期によって決定されます。手術、放射線療法、化学療法、分子標的治療、免疫療法などが考えられます。治療コースの選択は、腫瘍の大きさや位置、周囲のリンパ節や体の離れた部位への進行の有無、患者の全身状態など、多くの変数に影響されます。

市場力学

非小細胞肺がん治療に対するFDA承認の増加が世界の非小細胞肺がん市場の成長を牽引

2022年8月、FDAが承認した検査で検出された間葉上皮移行（MET）エクソン14スキップにつながる変異を腫瘍が有する転移性非小細胞肺がん（NSCLC）の成人患者に対し、食品医薬品局はこの疾患に対するカプラチニブ（タブレクタ、ノバルティスファーマシューティカルズ社）の通常承認を与えました。

さらに2022年11月、リジェネロン・ファーマシューティカルズ社は、EGFR、ALK、ROS1異常のない進行非小細胞肺がん（NSCLC）成人患者の一次治療として、PD-1阻害薬リブタヨ（cemiplimab-rwlc）をプラチナ製剤ベースの化学療法と併用することをFDAが承認したと発表しました。

この治療法の対象は、局所進行または転移性進行腫瘍で、確定化学放射線療法または外科的切除が無効な患者です。この併用療法は、組織型やPD-L1発現に関係なく、患者の治療に使用することができます。

研究活動の活発化が世界の非小細胞肺がん市場の成長を牽引

2023年7月、アストラゼネカと第一三共が開発したTROP2指向性抗体薬併用療法は、最初の第III相データで、前治療歴のある局所進行性または転移性疾患において、従来の化学療法と比較して統計学的に有意な無増悪生存期間の延長を示しました。

TROPION-Lung01の第III相試験から得られた有望なハイレベルの知見によると、少なくとも1つの前治療歴を有する局所進行性または転移性非小細胞肺がん（NSCLC）患者において、Datopotamab deruxtecan（Dato-DXd）は、現在の標準治療であるドセタキセルと比較して、主要評価項目である無増悪生存期間（PFS）において統計学的に有意な改善を示しました。

二重主要評価項目である全生存期間（OS）において、データポタマブ・デルクステカンがドセタキセルに対して有利な傾向が早期に認められたが、データが成熟していなかったため、今回の中間解析では所定の統計学的有意水準には達しなかっています。実験は予定通り進められ、より成熟した段階でOSが評価されます。

非小細胞肺がん治療に伴う副作用が世界の非小細胞肺がん市場の成長を妨げる

非小細胞肺がん治療に伴う副作用が市場成長を抑制しています。免疫介在性の副作用は、重篤であったり致死的であったりする可能性があり、あらゆる臓器系や組織で起こり、一度に多くの身体系に影響を及ぼす可能性があります。肺炎、大腸炎、肝炎、内分泌障害、腎炎、皮膚反応、固形臓器移植拒絶反応、同種造血幹細胞移植による障害は、KEYTRUDAによる治療中または治療後にいつ起こるかわからない免疫介在性副作用のいくつかの例です。

さらに、KEYTRUDAに対する重篤または致死的な注入関連反応も起こり得ます。妊婦に投与された場合、KEYTRUDAはその作用機序により胎児に害を及ぼす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 非小細胞肺がん治療に対するFDA承認の増加
  • 抑制要因
    • 非小細胞肺がんに伴う副作用
  • 機会
    • 研究活動の増加
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 薬剤クラス別

• 上皮成長因子受容体（EGFR）阻害剤
• 未分化リンパ腫キナーゼ（ALK）阻害薬
• ROS1阻害剤
• BRAF阻害剤
• その他

第10章 タイプ別

• 扁平上皮がん
• 大細胞がん
• 腺がん
• その他

第11章 治療法別

• 化学療法
• 標的療法
• 免疫療法

第12章 エンドユーザー別

• 病院
• 在宅医療
• 専門クリニック
• その他

第13章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第14章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第15章 企業プロファイル

• Eli Lilly and Company
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Sanofi
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Pfizer Inc.
• AstraZeneca
• Boehringer Ingelheim
• Bristol-Myers Squibb Company
• Astellas

第16章 付録

Overview

Global Non Small-Cell Lung Cancer Market reached US$ 25.4 billion in 2022 and is expected to reach US$ 47.4 billion by 2030 growing with a CAGR of 8.4% during the forecast period 2023-2030. The non-small-cell lung cancer market is driven by factors such as increasing incidence, advancements in research and development, personalized medicine, pipeline developments, and government initiatives.

The non-small-cell lung cancer treatment strategy is determined by the cancer's stage, which reflects how far along it has progressed. Surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy are all possible forms of treatment. The selection of a course of treatment is impacted by a number of variables, including the size and location of the tumor, whether it has progressed to surrounding lymph nodes or distant regions of the body, and the patient's general condition.

Market Dynamics

The Increasing FDA Approval for Non-Small-Cell Lung Cancer Treatment is Driving the Global Non-Small-Cell Lung Cancer Market Growth

In August 2022, for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food and Drug Administration has given capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) regular approval for this diseases.

In addition, in November 2022, Regeneron Pharmaceuticals, Inc. announced that the FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line Treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who do not have EGFR, ALK, or ROS1 aberrations.

Patients must either have locally or metastatically advanced tumors that are not amenable to definitive chemoradiation or surgical excision. This combination may be used to treat patients regardless of histology or PD-L1 expression.

The Increasing Research Activities are Driving The Global Non-Small-Cell Lung Cancer Market Growth

In July 2023, the TROP2-directed antibody drug combination developed by AstraZeneca and Daiichi Sankyo showed a statistically significant increase in progression-free survival compared to conventional chemotherapy in previously treated locally progressed or metastatic illness in the first Phase III data.

Datopotamab deruxtecan (Dato-DXd) showed a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy, according to encouraging high-level findings from the TROPION-Lung01 Phase III trial.

There was an early tendency in favor of datopotamab deruxtecan versus docetaxel for the dual primary endpoint of overall survival (OS), but it did not reach the predetermined level of statistical significance at this interim analysis because the data were not mature. The experiment will proceed as scheduled to evaluate OS at a more mature stage.

Side Effects Associated with Non-Small-Cell Lung Cancer Therapy are Hampering the Global Non-Small-Cell Lung Cancer Market Growth

Side effects associated with non-small-cell lung cancer therapy restraining the market growth. Adverse immune-mediated reactions, which can be serious or lethal, can happen in any organ system or tissue and can influence many bodily systems at once. Pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic responses, solid organ transplant rejection, and difficulties from allogeneic hematopoietic stem cell transplantation are a few examples of immune-mediated adverse reactions that can happen at any moment during or after therapy with KEYTRUDA.

Additionally, serious or fatal infusion-related responses to KEYTRUDA are possible. When given to a pregnant woman, KEYTRUDA has the potential to harm the fetus due to its mode of action.

Segment Analysis

The global non-small-cell lung cancer market is segmented based on type, treatment, end-user and region.

The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 45.1% of the non-small-cell lung cancer market in 2022. Surgery is still the most common form of treatment for people with stage IB, stage II, and stage IIIA non-small cell lung cancer, despite the fact that there have been numerous advancements for patients with metastatic disease.

The U.S. Food and Drug Administration (FDA) approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent in January 2023 for adjuvant Treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimeters [cm]), II, or IIIA non-small cell lung cancer (NSCLC).

Geographical Penetration

North America Holds a Dominant Position in the Global Non-Small-Cell Lung Cancer Market

North America is estimated to hold around 38.3% of the total market share throughout the forecast period. Lung cancer is the second most prevalent cancer to be diagnosed globally. With 81% of all lung cancer diagnoses in the US being NSCLC, it is the most prevalent kind of disease. Lung cancer will be discovered in 238,340 adults in the United States in 2023 (117,550 men and 120,790 women). In 2020, there will likely be 2,206,771 lung cancer diagnoses worldwide. Both NSCLC and small cell lung cancer are included in these statistics.

Black and White women currently experience lower incidence rates than men. Black males are 12% more likely than White men to have lung cancer, which is the group with the highest lung cancer rates. Lung cancer is 16% less likely to affect Black women than White women. Lung cancer risk rises with advancing age. Approximately 53% of those with the condition are 70 years of age or older, according to estimates. People 65 and older are thought to be the target audience for 83% of diagnoses. While the majority of cases in women are discovered between the ages of 75 and 79, men are most likely to be diagnosed with NSCLC between the ages of 80 and 84.

Competitive Landscape

The major global players in the market include: Eli Lilly and Company, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, and Astellas among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the non-small-cell lung cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Clinical trials and research projects linked to NSCLC treatments could be affected if the conflict affects healthcare institutions and services. The creation of novel treatments could be slowed down by research pauses or interruptions.

Geopolitical unpredictability may cause a decline in international investments, especially those in the healthcare sector. This might have an effect on the amount of money allocated to NSCLC research, development, and infrastructure.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the non-small-cell lung cancer market to improve various aspects of data analysis. Radiologists can use AI algorithms to help them analyze CT and X-ray scan data to look for patterns and abnormalities that can indicate NSCLC. These algorithms can aid in enhancing the speed and accuracy of diagnosis. In addition, medical images of lung tumors and lesions can be segmented using AI to provide a more thorough understanding of their size, shape, and location. Planning and monitoring treatments need the use of this information.

By Drug Class

• Epidermal Growth Factor Receptor (EGFR) Inhibitors
• Anaplastic Lymphoma Kinase (ALK) Inhibitors
• ROS1 Inhibitors
• BRAF Inhibitors
• Others

By Type

• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Others

By Treatment

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By End-user

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

UK

France

Italy

Spain

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In December 2022, the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, hosted by the Agency for Science, Technology and Research of Singapore (A*STAR), and pioneering pharmaceutical technology company XtalPi, announced a strategic partnership to find new Treatment options for non-small cell lung cancer (NSCLC).

Why Purchase the Report?

• To visualize the global non-small-cell lung cancer market segmentation based on the type, treatment, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of non-small-cell lung cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global non-small-cell lung cancer market report would provide approximately 61 tables, 69 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Type
• 3.3. Snippet by Treatment
• 3.4. Snippet by End-user
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with non-small-cell lung cancer
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing research activities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Drug Class

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.1.2. Market Attractiveness Index, By Drug Class
• 9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
• 9.4. ROS1 Inhibitors
• 9.5. BRAF Inhibitors
• 9.6. Others

10. By Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.1.2. Market Attractiveness Index, By Type
• 10.2. Squamous Cell Carcinoma*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Large Cell Carcinoma
• 10.4. Adenocarcinoma
• 10.5. Others

11. By Treatment

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.1.2. Market Attractiveness Index, By Treatment
• 11.2. Chemotherapy*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Targeted Therapy
• 11.4. Immunotherapy

12. By End-user

• 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
• 12.1.2. Market Attractiveness Index, By End-user
• 12.2. Hospitals*
  • 12.2.1. Introduction
  • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 12.3. Homecare
• 12.4. Specialty Clinics
• 12.5. Others

13. By Region

• 13.1. Introduction
  • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 13.1.2. Market Attractiveness Index, By Region
• 13.2. North America
  • 13.2.1. Introduction
  • 13.2.2. Key Region-Specific Dynamics
  • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.2.7.1. U.S.
    • 13.2.7.2. Canada
    • 13.2.7.3. Mexico
• 13.3. Europe
  • 13.3.1. Introduction
  • 13.3.2. Key Region-Specific Dynamics
  • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.3.7.1. Germany
    • 13.3.7.2. U.K.
    • 13.3.7.3. France
    • 13.3.7.4. Italy
    • 13.3.7.5. Spain
    • 13.3.7.6. Rest of Europe
• 13.4. South America
  • 13.4.1. Introduction
  • 13.4.2. Key Region-Specific Dynamics
  • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.4.7.1. Brazil
    • 13.4.7.2. Argentina
    • 13.4.7.3. Rest of South America
• 13.5. Asia-Pacific
  • 13.5.1. Introduction
  • 13.5.2. Key Region-Specific Dynamics
  • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.5.7.1. China
    • 13.5.7.2. India
    • 13.5.7.3. Japan
    • 13.5.7.4. Australia
    • 13.5.7.5. Rest of Asia-Pacific
• 13.6. Middle East and Africa
  • 13.6.1. Introduction
  • 13.6.2. Key Region-Specific Dynamics
  • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

14. Competitive Landscape

• 14.1. Competitive Scenario
• 14.2. Product Benchmarking
• 14.3. Company Share Analysis
• 14.4. Key Developments and Strategies

15. Company Profiles

• 15.1. Eli Lilly and Company*
  • 15.1.1. Company Overview
  • 15.1.2. Product Portfolio and Description
  • 15.1.3. Financial Overview
  • 15.1.4. Key Developments
• 15.2. Sanofi
• 15.3. Novartis AG
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Merck & Co., Inc.
• 15.6. Pfizer Inc.
• 15.7. AstraZeneca
• 15.8. Boehringer Ingelheim
• 15.9. Bristol-Myers Squibb Company
• 15.10. Astellas

LIST NOT EXHAUSTIVE

16. Appendix

• 16.1. About Us and Services
• 16.2. Contact Us